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S U M M A R Y
Objectives: On the background of a high prevalence of HHV-8 infection in pre-pubertal Central African
children, this study investigated the potential for in utero transmission of HHV-8.
Patients: Gabonese pregnant women were invited to provide peripheral and cord blood samples for
serological and PCR diagnostics of HHV-8 infection at delivery for this cross-sectional survey.
Results: Out of 344 participants 120 (35%, 95% CI: 30-40%) were serologically positive for HHV-8. 31%
(95% CI: 22-40%) of cord blood samples of seropositive women had detectable IgG antibodies. Among all
seropositive participants HHV-8 was detected by PCR in one maternal peripheral blood sample at
delivery (1%, 95% CI: 0.2-7%) and in none of cord blood samples. There was no association between
demographic characteristics and infection status. Similarly, there was no difference in risk for premature
delivery, low birth weight, and maternal anaemia in HHV-8 seropositive women.
Discussion: These data suggest a high seroprevalence of HHV-8 infection in pregnant women, however
viraemia at delivery does not commonly occur in Central Africa. Based on these observations it may be
speculated that infection of children may occur more commonly either antepartum or later on in infancy
and childhood.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Human herpes virus-8 (HHV-8) – also known as Kaposi’s
sarcoma associated herpes virus – is an infectious agent causing
Kaposi’s sarcoma, primary effusion lymphoma, and multicentric
Castleman’s disease.1–6 HHV-8 infection is thought to be primarily
transmitted by sexual contact.2,7,8 However, the observation of
high seroprevalence in pre-pubertal children residing in Africa and
the Western and Eastern Mediterranean region9–12 suggests other* Corresponding author. Institut fu¨r Tropenmedizin, University of Tu¨bingen,
72074 Tu¨bingen, Germany. Tel.: +49-7071-2987179; fax: +49-7071-295189.
E-mail address: michael.ramharter@medizin.uni-tuebingen.de (M. Ramharter).
http://dx.doi.org/10.1016/j.ijid.2015.08.004
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).epidemiologically relevant routes of transmission. However, little
is known about the potential for vertical transmission of HHV-8.
Active infection during pregnancy with several herpes viruses
may affect the human placenta, including herpes simplex virus-1,
varicella-zoster virus, and cytomegalovirus, potentially leading to
placental insufﬁciency, premature delivery, miscarriage, or major
congenital abnormalities.13–15 To date, only limited data are
available about the impact of maternal HHV-8 infection on birth
outcomes and about the potential for vertical transmission of HHV-
8. Previous studies report that seropositivity in newborns was
mostly caused by transplacental passage of maternal antibo-
dies.9,16 However, HHV-8 DNA was detected in newborns in
Zambia in peripheral mononuclear cells (PBMCs)17 indicating
vertical transmission during pregnancy. To further investigate theciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Analysis of baseline characteristics as potential factors associated with HHV-8
seropositivity in pregnant women in Gabon
Parameters Total number of
participants
HHV-8 seropositive
n(%)
p-Valueb
Age group
14-17 45 16 (36%) 0.944
18-20 92 34 (37%)
21-30 139 48 (35%)
31-49 68 22 (32%)
Literacy
Literate 283 102 (36) 0.331
Illiterate 61 18 (30%)
Gravidity
Primigravid 86 28 (33%) 0.070
Secundigravid 71 33 (46%)
Multigravid 187 59 (32%)
Syphilisa
Positive 5 2 (40%) 0.825
Negative 332 117 (35%)
a Syphilis infection was assessed by Rapid Plasma Reagin testing.
b Chi-squared test.
Table 2
Birth outcome and HHV-8 infection in pregnant women in Gabon
Parameters n HHV-8 seropositive n(%) p-Value
Delivery
Livebirth 336 119 (35%) 0.179
Stillbirth 8 1 (13%)
Delivery characteristics*
Vaginal 325 113 (35%) 0.965
Caesarean 17 6 (35%)
Delivery anaemia*
No anaemia 192 66 (34%) 0.818
Anaemiab 149 53 (36%)
Term delivery*
Normal 314 114 (36%) 0.197
Pretermc 15 3 (20%)
Birth weight*
Normal 276 97 (35%) 0.724
Lowd 64 21 (33%)
a HHV-8 infection classiﬁed based on serology.
b anaemia: haemoglobin < 11.0 g/dl.
c preterm delivery: < 37 weeks of gestation.
d low birth weight: deﬁned as < 2500 g at delivery.
* Data not available for all 344 individuals.
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infection on birth outcomes this study assessed the prevalence of
HHV-8 infection in pregnant women at delivery and in cord blood
samples of their offspring in the Central African country Gabon.
2. Material and Methods
This study was conducted at the Centre de Recherches
Me´dicales de Lambare´ne´ at the Albert Schweitzer Hospital in
Lambare´ne´, and the Ngounie´ Medical Research Centre in Fouga-
mou, Gabon.18 Pregnant women participating in a multicentre
study evaluating alternative drugs for intermittent preventive
treatment of malaria in pregnancy (MIPPAD study: ‘‘Evaluation of
the safety and efﬁcacy of meﬂoquine as intermittent preventive
treatment of malaria in pregnancy (IPTp; NCT 00811421).’’) were
invited to participate in this cross-sectional study by providing
written informed consent.19,20 In accordance with inclusion
criteria of MIPPAD only HIV-negative women were recruited.
Other major inclusion criteria were gestational age 28 weeks, no
history of allergy to sulfa drugs or meﬂoquine (MQ), no history of
severe renal, hepatic, psychiatric, or neurological disease and no
recent MQ or halofantrine treatment. No further inclusion or
exclusion criteria other than speciﬁc informed consent for this
study were applied.
Peripheral maternal and cord blood samples were obtained at
delivery. Blood samples were centrifuged at 2500 rpm for
10 minutes to obtain plasma for the detection of speciﬁc antibodies
directed against latent nuclear antigen of HHV-8. Whole blood was
used for the detection of virus speciﬁc DNA by PCR. Plasma samples
were tested at a 1/20 dilution for the presence of HHV-8-speciﬁc
IgG by an indirect immunoﬂuorescence assay (HHV-8 IFA; ABI,
Columbia, MD) following instructions by the manufacturer. No
quantiﬁcation of antibody titres was performed. In this assay
speciﬁc HHV-8 antibodies binding to the antigen of infected cells
were visualized after incubation with Fluorescein Isothiocyanate
under a ﬂuorescence microscope.21 Based on the high sensitivity of
the serologic test, only seropositive samples were further analysed
by PCR.
DNA was extracted from maternal and cord blood using
QIAamp tissue kit (Qiagen, Bechman Instruments Inc, US). DNA
extracts were further assayed by RT-PCR using the LightCycler1
carousel-based system. Ampliﬁcation was carried out in a 15 ml
PCR master mix containing 10 pmol/ml of each primer,22,23 3 mM
of MgCl2, 1x Lightcycler1 LightCycler1 FastStart DNA Master SYBR
Green I (Roche Diagnostic GmbH, Mannheim, Germany) and 1.5 ml
of DNA. To detect HHV-8, two sets of primers were used. The ﬁrst
set of primers ampliﬁed a 233-bp region of open-reading frame 26
(ORF26);23 the second set of primers was speciﬁc for the ORF25
region.22
Birth weight was measured within 24 h after birth in all
newborns. For estimation of gestational age, the Ballard score was
used.
Data were recorded on paper record forms, transcribed into an
electronic database, and further analysed (JMP 7.0, SAS Institute
Inc., NC). Ethics clearance of this study was obtained by the Comite´
d’Ethique du Centre de Rercherches Me´dicales de Lambare´ne´, at
the Albert Schweitzer Hospital in Gabon.
3. Results
Between May 2010 and October 2011, 344 pregnant women
delivering at the two health care centres were recruited for his
study. Mean age at recruitment was 24 years ranging from 14 to
49 years, and mean birth weight was 2,954 g (SD: 581 g).
A total of 120 pregnant women (35%, 95% CI: 30-40%) tested
positive for HHV-8 speciﬁc antibodies in the serological assay.Proportions of seropositivity in primigravidae, secundigravidae
and multigravidae were 33%, 47%, and 32%, respectively. No
difference in the distribution of baseline and demographic
characteristics including age and parity were observed in HHV-8
positive versus negative individuals (Table 1). HHV-8 prevalence
was comparable in syphilis positive (40%, 95% CI: 11.8-76.9%) and
negative individuals (35%, 95% CI: 30.3-40.5%; Table 1), respec-
tively. No association between HHV-8 seropositivity and adverse
birth outcomes was found (Table 2).
Ninety-eight cord blood samples from seropositive women
were collected for further serological analysis. Among those,
30 cord blood samples (31%, 95% CI: 22-40%) tested positive for the
presence of HHV-8 speciﬁc IgG. 76 paired samples from maternal
and cord blood were available for further PCR analysis (inadequate
DNA extraction in 22 samples). One maternal blood sample (1%,
95% CI: 0-7%) yielded a positive result for HHV-8 DNA. All other
maternal samples and all cord blood samples were negative in PCR
analysis.
4. Discussion
This study demonstrates a high prevalence of HHV-8 seroposi-
tive HIV negative pregnant women indicating that HHV-8 infection
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Interestingly, the proportion of illiterate and very young pregnant
women – an important surrogate marker for socioeconomic status
– was not different between infected and uninfected individuals.24
This ﬁnding indicates that HHV-8 is rather uniformly distributed in
this African population without evidence for particular risk factors
for HHV-8 infection. Importantly, there was no difference in
prevalence of HHV-8 seroprevalence depending on the age and
parity of pregnant women. Interestingly, prevalence of syphilis
was low in both groups. The low rate of syphilis in our cohort might
be explained by the fact that HIV was deﬁned as an exclusion
criterion and thus women with high risk sexual behaviour were
excluded. In Europe and North America unprotected sexual
contacts are considered to be the major route of transmission
for HHV-8.2,25 However, in Central Africa there is epidemiological
evidence for early increase of HHV-8 seroprevalence during
childhood. A sero-epidemiological survey in a highly endemic
region in Uganda showed that HHV-8 transmission occurs during
childhood increasing progressively up to 50% in adults. Similarly, a
Cameroonian study reported a gradual increase of seropositivity
from 13% in 7-24 month olds to 39% in 12-14 year old children,
reaching 45% in adult women.9,10 These data from the Central
African region demonstrate that routes of transmission other than
by sexual contact play the most important role for transmission of
HHV-8 in this pre-pubertal population. Importantly, other modes
of transmission including exposure to saliva are increasingly
incriminated for the transmission of HHV-8 and may potentially
explain the epidemiological pattern of HHV-8 transmission in
Central Africa.26
In our study, seropositivity was detected in 31% of cord blood
samples of seropositive women. This ﬁnding may be explained by
passive transfer of maternal IgG antibodies and is per se no
conclusive proof for vertical transmission. Importantly, all cord
blood samples were tested negative for the presence of HHV-8 DNA
in PCR analysis. This ﬁnding indicates that infection and
subsequent viraemia in the newborn does not occur commonly.
However, this study did not investigate the potential for intra-
partum transmission of HHV-8. In addition longitudinal sampling
of pregnant women was not performed during pregnancy due to
the cross section study design, which constitutes a limitation of our
study. Further follow up and blood sampling during the ﬁrst year of
life would have been necessary to address this research question
but was beyond the scope of this work.
Whereas active infections with other herpes viruses during
pregnancy are reportedly associated with adverse pregnancy
outcome including spontaneous abortion, premature delivery,
and miscarriage,13–15 this survey did not show such an associa-
tion for HHV-8 seropositive pregnant women. However, viraemia
was not detected in all but one woman and therefore the sample
size of this study was not large enough to reliably detect more
subtle risk differences between viraemic and non-infected
individuals.
In summary these data conﬁrm a uniformly high prevalence
of HHV-8 seropositivity in Gabon. No evidence for in utero
transmission of HHV-8 and viraemia in cord blood was found in
this study. Future investigations should further characterize
transmission characteristics in infancy and childhood in Central
Africa potentially focussing on oro-oral transmission patterns.
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